PT2316425T - Formulações líquidas compreendendo um agente ativo, glicerina e sorbitol - Google Patents

Formulações líquidas compreendendo um agente ativo, glicerina e sorbitol

Info

Publication number
PT2316425T
PT2316425T PT10188391T PT10188391T PT2316425T PT 2316425 T PT2316425 T PT 2316425T PT 10188391 T PT10188391 T PT 10188391T PT 10188391 T PT10188391 T PT 10188391T PT 2316425 T PT2316425 T PT 2316425T
Authority
PT
Portugal
Prior art keywords
glycerine
sorbitol
active agent
liquid formulations
formulations
Prior art date
Application number
PT10188391T
Other languages
English (en)
Portuguese (pt)
Inventor
Bubnis William
Shield Stephanie
Alley Amanda
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PT2316425T publication Critical patent/PT2316425T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT10188391T 2006-02-21 2007-02-16 Formulações líquidas compreendendo um agente ativo, glicerina e sorbitol PT2316425T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77463406P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
PT2316425T true PT2316425T (pt) 2018-11-13

Family

ID=38283964

Family Applications (2)

Application Number Title Priority Date Filing Date
PT07751095T PT1986606T (pt) 2006-02-21 2007-02-16 Formulações líquidas contendo fenilefrina
PT10188391T PT2316425T (pt) 2006-02-21 2007-02-16 Formulações líquidas compreendendo um agente ativo, glicerina e sorbitol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT07751095T PT1986606T (pt) 2006-02-21 2007-02-16 Formulações líquidas contendo fenilefrina

Country Status (12)

Country Link
US (4) US8940796B2 (tr)
EP (2) EP1986606B1 (tr)
AU (1) AU2007217799B2 (tr)
CA (1) CA2642048C (tr)
ES (2) ES2728823T3 (tr)
HU (2) HUE039382T2 (tr)
PE (2) PE20071310A1 (tr)
PL (2) PL1986606T3 (tr)
PT (2) PT1986606T (tr)
TR (2) TR201815803T4 (tr)
TW (1) TWI482620B (tr)
WO (1) WO2007098128A2 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
RU2008151945A (ru) * 2006-06-01 2010-07-20 Шеринг Корпорейшн (US) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
JP5175278B2 (ja) * 2006-06-01 2013-04-03 エムエスディー コンシューマー ケア， インコーポレイテッド 結腸吸収のためのフェニレフリン薬学的製剤および組成物
PE20120075A1 (es) * 2006-06-01 2012-02-20 Merck Sharp & Dohme Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
RU2009148862A (ru) * 2007-06-01 2011-07-20 Шеринг-Плау Хельскер Продактс, Инк. (Us) Фармацевтическая композиция, включающая субстрат и покрытие, содержащее активный ингридиент и поливиниловый спирт
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015137829A1 (en) * 2014-03-12 2015-09-17 Angeles Relinda G Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
CN104983732B (zh) * 2015-05-28 2018-05-04 华润三九医药股份有限公司 一种布洛肾素那敏片及其制备方法
CN104922124B (zh) * 2015-05-28 2017-06-30 华润三九医药股份有限公司 一种肾素那敏片及其制备方法
WO2020013973A1 (en) * 2018-07-09 2020-01-16 Bayer Healthcare Llc An aqueous-based composition containing xantan gum as inhibitor of microbial growth
CN109125257B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚愈创肾素口服液及其制备方法
CN109045003B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚拉明肾素口服液及其制备方法
CN109044968B (zh) * 2018-10-18 2020-12-01 云南大唐汉方制药股份有限公司 氨酚右美肾素口服液及其制备方法
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN110507607A (zh) * 2019-09-27 2019-11-29 葵花药业集团北京药物研究院有限公司 苯海拉明肾素口服液及其制备方法和用途
US20230012144A1 (en) 2019-12-23 2023-01-12 Nutra Essential Otc, S.L. Liquid composition comprising ibuprofen and phenylephrine
US20210228507A1 (en) * 2020-01-22 2021-07-29 Nevakar Inc. Phenylephrine Hydrochloride Compositions and Containers
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法
CN112076183A (zh) * 2020-08-28 2020-12-15 北京博达绿洲医药科技研究有限公司 包含盐酸去氧肾上腺素液体组合物
CN113081958B (zh) * 2021-05-01 2022-05-03 安徽新世纪药业有限公司 一种地氯雷他定口服溶液及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
AU670567B2 (en) 1992-03-05 1996-07-25 American Home Products Corporation Pharmaceutical coated cores
US5405604A (en) * 1992-10-16 1995-04-11 The Procter & Gamble Company Concentrated mouthrinse for efficient delivery of antimicrobials
WO1996003976A1 (en) 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
DE69901936T2 (de) * 1998-01-30 2002-11-28 Novartis Consumer Health Sa Nasale lösungen
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
NZ530889A (en) * 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
US6462094B1 (en) * 2001-08-22 2002-10-08 Medpointe Healthcare Inc. Decongestant/expectorant compositions
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US6509492B1 (en) 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
CA2590834A1 (en) 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositons and methods for stabilizing active pharmaceutical ingredients
US20070160689A1 (en) 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
RU2008151945A (ru) 2006-06-01 2010-07-20 Шеринг Корпорейшн (US) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина

Also Published As

Publication number Publication date
US11419938B2 (en) 2022-08-23
PL1986606T3 (pl) 2019-08-30
US8940796B2 (en) 2015-01-27
TWI482620B (zh) 2015-05-01
AU2007217799B2 (en) 2012-12-13
AU2007217799A1 (en) 2007-08-30
WO2007098128A3 (en) 2007-10-11
CA2642048A1 (en) 2007-08-30
EP2316425B1 (en) 2018-08-29
PE20071310A1 (es) 2007-12-12
TW200800143A (en) 2008-01-01
PE20110010A1 (es) 2011-01-12
EP1986606B1 (en) 2019-04-10
US20150150976A1 (en) 2015-06-04
US20190209688A1 (en) 2019-07-11
HUE039382T2 (hu) 2018-12-28
US20070197661A1 (en) 2007-08-23
US20170333561A1 (en) 2017-11-23
TR201906970T4 (tr) 2019-06-21
TR201815803T4 (tr) 2018-11-21
ES2692890T3 (es) 2018-12-05
CA2642048C (en) 2015-11-24
US11406712B2 (en) 2022-08-09
EP1986606A2 (en) 2008-11-05
WO2007098128A2 (en) 2007-08-30
EP2316425A1 (en) 2011-05-04
US9801941B2 (en) 2017-10-31
PT1986606T (pt) 2019-06-12
HUE043620T2 (hu) 2019-08-28
ES2728823T3 (es) 2019-10-28
PL2316425T3 (pl) 2019-01-31

Similar Documents

Publication Publication Date Title
PT2316425T (pt) Formulações líquidas compreendendo um agente ativo, glicerina e sorbitol
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
IL184563A (en) Pharmaceutical foam formulations and their use
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2046290A4 (en) AQUEOUS DRONABINOL FORMULATIONS
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
PL2594248T3 (pl) Połączenie składników czynnych i jego zastosowanie
ZA200902920B (en) Composition comprising oligogalacturonans and polycationic saccharides
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
PL3001905T3 (pl) Kombinacje substancji czynnej o właściwościach owadobójczych i roztoczobójczych
IL202770A0 (en) Active ingredient suspensions in glycerine
IL173762A0 (en) A device and method for the prolonged delivery of an active agent to a body cavity
PL2194784T3 (pl) Kombinacje substancji czynnych o właściwościach owadobójczych i roztoczobójczych
IL192206A0 (en) Topical mecamylamine formulations for ocular administration and uses thereof
PT1795186E (pt) Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa
PL2923576T3 (pl) Kombinacje substancji czynnych o właściwościach owadobójczych i roztoczobójczych
EP1900374A4 (en) ANGIOGENETIC AGENT CONTAINING ADRENOMEDULIN AS ACTIVE INGREDIENT
IL209029A0 (en) Condom with localized active agent
PL2084272T3 (pl) Klonowanie, ekspresja oraz zastosowanie kwaśnych lizofosfolipaz
GB0614393D0 (en) Perfume Formulation
ZA200804086B (en) Stable pharmaceutical formulations containing escitalo-pram and bupropion
ZA200805938B (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
EP2348019A4 (en) 1,2-DIAZETTIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME